Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

“Human Medicines” page
Randomized study combining interferon & glatiramer acetate in multiple sclerosis.
Breastfeeding and multiple sclerosis relapses: a meta-analysis.
Bilateral optic neuritis in a patient with Behçet's disease who respond to therapeutic plasma exchange.
Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis.
Origin, fate and dynamics of macrophages at central nervous system interfaces.
Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE.
Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study.
Oligodendrocytes and progenitors become progressively depleted within chronically demyelinated lesions.
Rituximab does not reset defective early B cell tolerance checkpoints.
Adherence to Disease Modifying Drugs among Patients with Multiple Sclerosis in Germany: A Retrospective Cohort Study.
Discovery of CNS Penetrant CXCR2 Antagonists for the Potential Treatment of CNS Demyelinating Disorders.
The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group.
Dimethyl fumarate for multiple sclerosis.
Pathogenic aquaporin-4 reactive T cells are sufficient to induce mouse model of neuromyelitis optica.
[Th17-mediated relapsing-remitting multiple sclerosis is nonresponsive to interferon-β1b].
Biogen Data at 2016 AAN Annual Meeting Highlight Its Expansive Portfolio of MS Therapies That Meets Diverse Needs of Patients
Neuroimmunology: Phase II trial demonstrates efficacy of erythropoietin in optic neuritis.
Rebif® Versus Copaxone® in the Treatment of Relapsing Remitting Multiple Sclerosis
Multiple sclerosis: pathogenesis and treatment.
European Commission approves Genzyme’s multiple sclerosis treatment Lemtrada™ (alemtuzumab)
Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation.
Understanding the Metabolic Consequences of Human Arylsulfatase A Deficiency through a Computational Systems Biology Study.
White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis.

Pages